The Swiss government is set to release contracts related to its procurement of COVID-19 vaccines, reversing its previous stance and accepting a recent ruling by the Federal Administrative Court. The decision, announced on Monday, March 9, 2026, follows years of debate and legal challenges regarding transparency surrounding the deals struck during the pandemic. This move promises to shed light on the pricing, delivery conditions, and liability clauses associated with the vaccines acquired from companies like Moderna, Novavax, Pfizer, and others.
For years, the Swiss Federal Office of Public Health (BAG) resisted calls for full disclosure, citing concerns about protecting business secrets and maintaining Switzerland’s negotiating position for future pandemic preparedness. Yet, the Federal Administrative Court sided with complainants who argued for greater public access to the information under the country’s public access laws. The court determined that the BAG’s reasons for redacting significant portions of the contracts – in some cases, entire pages – were insufficient. This ruling underscores the importance of transparency in public health emergencies and the public’s right to recognize how taxpayer money is spent.
Court Ruling Forces Transparency on Vaccine Contracts
The legal battle began in 2022 when the BAG initially released the COVID-19 vaccine procurement contracts, but with extensive redactions. According to reporting from NZZ.ch, one contract with Pfizer was almost entirely blacked out, with 27 pages containing no readable text. This lack of transparency fueled criticism from both skeptical groups concerned about vaccine safety and members of the National Council who sought greater accountability. Rémy Wyssmann, a lawyer and SVP-cantonal councilor from Solothurn, spearheaded the legal challenge, filing a complaint against the BAG.
The Federal Administrative Court’s February 17, 2026, ruling sided with Wyssmann and other complainants, compelling the government to release the unredacted contracts for Moderna and Novavax. The court rejected the BAG’s arguments that releasing the full contracts would harm Switzerland’s reputation or its ability to negotiate favorable deals in future health crises. The court reasoned that the pandemic had largely subsided, making the risk of jeopardizing future negotiations less pressing. The court suggested that the disclosure might only be “unpleasant” for the government, potentially allowing for comparisons with current pricing on the specialty list.
Concerns Over Commercial Secrets and Future Negotiations
The BAG initially argued that disclosing the contracts would reveal commercially sensitive information belonging to the vaccine manufacturers, potentially harming their business interests. They also expressed concern that revealing the prices paid by Switzerland could weaken its bargaining position in future pandemic situations. As reported by 20 Minuten, the government feared being at a disadvantage when procuring vaccines in a future pandemic, potentially facing higher prices or less favorable terms.
However, the court dismissed these concerns, stating that the risk of a new pandemic outbreak was uncertain, as were the number of manufacturers, prices, and conditions that would prevail in such a scenario. The court’s decision prioritizes the public’s right to access information about government spending and decision-making, particularly in matters of public health. The ruling aligns with principles of open government and accountability, allowing citizens to scrutinize how public funds were allocated during the pandemic.
What the Contracts May Reveal
The release of the unredacted contracts is expected to provide crucial details about several key aspects of the vaccine procurement process. Specifically, the public will likely gain insight into the per-dose cost of the vaccines from Moderna, Novavax, Pfizer, Janssen, AstraZeneca, and CureVac. The contracts will also clarify the delivery schedules and any associated penalties for delays. Perhaps most importantly, the agreements will outline the liability arrangements in the event of adverse effects from the vaccines – a point of significant public interest and debate during the pandemic.
The Swiss government has indicated it will not appeal the Federal Administrative Court’s decision. However, the vaccine manufacturers themselves retain the right to challenge the ruling in court to protect their confidential business information. The BAG has stated that access to the contracts will be granted once the court’s decision becomes legally binding, assuming the manufacturers do not pursue further legal action. This timeline suggests that the full contracts could be publicly available within the next 30 days, unless challenged by the pharmaceutical companies.
Key Takeaways
- The Swiss government will release unredacted contracts for COVID-19 vaccines from Moderna and Novavax after a ruling by the Federal Administrative Court.
- The court rejected the BAG’s arguments that releasing the contracts would harm Switzerland’s negotiating position or reveal commercial secrets.
- The contracts are expected to reveal details about vaccine pricing, delivery schedules, and liability arrangements.
- Vaccine manufacturers have the option to appeal the ruling to protect their confidential information.
This decision marks a significant victory for transparency and accountability in Switzerland’s handling of the COVID-19 pandemic. The release of these contracts will allow for a more thorough public understanding of the financial and legal aspects of the vaccine procurement process, fostering greater trust and informed debate. The case also sets a precedent for future access to government information related to public health emergencies, reinforcing the importance of open government principles.
The next step in this process will be to monitor whether the vaccine manufacturers choose to appeal the Federal Administrative Court’s ruling. If they do not, the BAG is expected to publish the unredacted contracts within the next 30 days. We will continue to follow this story and provide updates as they become available. Share your thoughts on this important development in the comments below.